Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

Background: The lenvatinib (LEN) plus everolimus (EVE) combination demonstrated improved progression-free survival over everolimus alone in a phase 2 trial (Study-205). Objective: To compare quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) between LEN + EVE and EVE...

Full description

Bibliographic Details
Main Authors: Chung-Han Lee, Yin Wan, Alan Smith, Ran Xie, Robert J. Motzer
Format: Article
Language:English
Published: Elsevier 2021-09-01
Series:European Urology Open Science
Subjects:
Lenvatinib
Quality-adjusted survival
Q-TWiST
Renal cell carcinoma
Targeted therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S266616832100118X

Internet

http://www.sciencedirect.com/science/article/pii/S266616832100118X

Similar Items